Freedom Capital Markets Downgrades Doximity to Hold, Raises Price Target to $27
Benzinga Newsdesk 1 month ago
NewsDowngradesAnalyst RatingsPrice Target
Freedom Capital Markets analyst Gene Mannheimer downgrades Doximity (NYSE:DOCS) from Buy to Hold and raises the price target from $24 to $27.
Freedom Capital Markets analyst Gene Mannheimer downgrades Doximity (NYSE:DOCS) from Buy to Hold and raises the price target from $24 to $27.